NCT05249075Completed
Micro-Tech FNB Needle to Obtain Tissue Specimens of Pancreas Malignancy for Personalized Based Chemotherapy
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Systemic chemotherapy can improve disease-related symptoms and/or prolong survival in patients with pancreatic cancer. Before the start of chemotherapy, the diagnosis pancreatic carcinoma must be confirmed by tumor tissue samples, which are often obtained during endoscopic ultrasound (EUS) by fine needle aspiration (FNA) or fine needle biopsy (FNB). Obtaining core biopsies by FNB has several potential benefits, such as making a more reliable diagnosis, performing immunohistochemistry for diagnostic reasons and in the future obtaining enough malignant cells to deliver personalized based chemotherapy regimen based on mutations detected by next generation sequencing. Obtaining high quality and sufficient tumor material is essential for genomic profiling with a preference of FNB over FNA. Up to now, no specific FNB needle has been found to be superior in diagnostic accuracy and in obtaining tissue for genomic profiling. In this study, we aim to evaluate the diagnostic accuracy of a new FNB needle (Micro-Tech Europe GmbH, Düsseldorf, Germany) and we study the adequacy of the obtained tissue samples for performing genetic sequencing.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 138 (actual)
- First submitted
- 10 Feb 2022
- Start date
- 1 Mar 2022
- Primary completion date
- 14 Aug 2025
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Pancreatic cancer
- NCT number
- NCT05249075
What you commit to
- Study type: Observational
- Participants enrolled: 138
- From 1 Mar 2022 to the primary completion date, 14 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Altered anatomy (e.g., after previous Whipple-operation, Roux-and-Y gastrojejunostomy)
Other
- Contra-indications to undergoing an EUS (e.g., oropharyngeal abnormalities)
- Contra-indications to the administration of benzodiazepines, propophol or opioids
- Pregnancy
- Insufficient knowledge of the Dutch language to be able to understand the patient information
Who the study is looking for
- 18 years and older
- Clinical suspicion of pancreatic adenocarcinoma
- Indication for obtaining EUS-guided histology of a suspected pancreatic lesion
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.